U.S. Biomarker-based Immunoassays Market (2025 - 2033) Size, Share & Trends Analysis Report By Sample (Blood, Saliva), By Product (Reagents & Kits, Consumables), By Biomarker, By Diseases, By End Use, And Segment Forecasts

Table of Contents

Chapter 1. Methodology and Scope
                    1.1. Market Segmentation & Scope
                    1.2. Market Definitions
                        1.2.1. Sample Segment
                        1.2.2. Product Segment
                        1.2.3. Biomarker Segment
                        1.2.4. Diseases Segment
                        1.2.5. End-use Segment
                    1.3. Information analysis
                        1.3.1. Market formulation & data visualization
                    1.4. Data validation & publishing
                    1.5. Information Procurement
                        1.5.1. Primary Research
                    1.6. Information or Data Analysis
                    1.7. Market Formulation & Validation
                    1.8. Market Biomarkerl
                    1.9. Total Market: CAGR Calculation
                    1.10. Objectives
                        1.10.1. Objective 1
                        1.10.2. Objective 2
Chapter 2. Executive Summary
                    2.1. Market Outlook
                    2.2. Segment Snapshot
                    2.3. Competitive Insights Landscape
Chapter 3. U.S. Biomarker-Based Immunoassays Market Variables, Trends & Scope
                    3.1. Market Lineage Outlook
                        3.1.1. Parent market outlook
                        3.1.2. Related/ancillary market outlook.
                    3.2. Market Dynamics
                        3.2.1. Market driver analysis
                            3.2.1.1. Rising demand for precision medicine and personalized therapies
                            3.2.1.2. Increasing prevalence of chronic and infectious diseases
                            3.2.1.3. Technological advancements in immunoassay platforms
                        3.2.2. Market restraint analysis
                            3.2.2.1. High cost of advanced biomarker assays and platforms
                    3.3. U.S. Biomarker-Based Immunoassays Market Analysis Tools
                        3.3.1. Industry Analysis – Porter’s
                        3.3.2. PESTEL Analysis
Chapter 4. U.S. Biomarker-Based Immunoassays Market: Sample Estimates & Trend Analysis
                    4.1. Segment Dashboard
                    4.2. U.S. Biomarker-Based Immunoassays Market Sample Movement Analysis
                    4.3. U.S. Biomarker-Based Immunoassays Market Size & Trend Analysis, by sample, 2021 to 2033 (USD Million)
                    4.4. Blood
                        4.4.1. Blood market estimates and forecasts 2021 to 2033 (USD Million)
                    4.5. Tissue
                        4.5.1. Tissue market estimates and forecasts 2021 to 2033 (USD Million)
                    4.6. Saliva
                        4.6.1. Saliva market estimates and forecasts 2021 to 2033 (USD Million)
                    4.7. Urine
                        4.7.1. Urine market estimates and forecasts 2021 to 2033 (USD Million)
Chapter 5. U.S. Biomarker-Based Immunoassays Market: Product Estimates & Trend Analysis
                    5.1. Segment Dashboard
                    5.2. U.S. Biomarker-Based Immunoassays Market Product Movement Analysis
                    5.3. U.S. Biomarker-Based Immunoassays Market Size & Trend Analysis, by product, 2021 to 2033 (USD Million)
                    5.4. Consumables
                        5.4.1. Consumables market estimates and forecasts 2021 to 2033 (USD Million)
                    5.5. Instruments/Analyzers
                        5.5.1. Instruments/Analyzers market estimates and forecasts 2021 to 2033 (USD Million)
                    5.6. Reagent & Kits
                        5.6.1. Reagent & kits market estimates and forecasts 2021 to 2033 (USD Million)
                    5.7. Services
                        5.7.1. Services market estimates and forecasts 2021 to 2033 (USD Million)
Chapter 6. U.S. Biomarker-Based Immunoassays Market: Biomarker Estimates & Trend Analysis
                    6.1. Segment Dashboard
                    6.2. U.S. Biomarker-Based Immunoassays Market Biomarker Movement Analysis
                    6.3. U.S. Biomarker-Based Immunoassays Market Size & Trend Analysis, by biomarkers, 2021 to 2033 (USD Million)
                    6.4. Safety & toxicity biomarkers
                        6.4.1. Safety & toxicity biomarkers market estimates and forecasts 2021 to 2033 (USD Million)
                    6.5. Efficacy & Pharmacodynamic Biomarkers
                        6.5.1. Efficacy & Pharmacodynamic Biomarkers market estimates and forecasts 2021 to 2033 (USD Million)
                    6.6. Predictive & Prognostic Biomarkers
                        6.6.1. Predictive & prognostic biomarkers market estimates and forecasts 2021 to 2033 (USD Million)
                    6.7. Surrogate/Exploratory Biomarkers
                        6.7.1. Surrogate/exploratory biomarkers market estimates and forecasts 2021 to 2033 (USD Million)
Chapter 7. U.S. Biomarker-Based Immunoassays Market: Diseases Estimates & Trend Analysis
                    7.1. Segment Dashboard
                    7.2. U.S. Biomarker-Based Immunoassays Market Diseases Movement Analysis
                        7.2.1. U.S. Biomarker-Based Immunoassays Market Size & Trend Analysis, by diseases, 2021 to 2033 (USD Million)
                    7.3. Cancer
                        7.3.1. Cancer market estimates and forecasts 2021 to 2033 (USD Million)
                    7.4. Cardiovascular Diseases
                        7.4.1. Cardiovascular diseases market estimates and forecasts 2021 to 2033 (USD Million)
                    7.5. Neurological Diseases
                        7.5.1. Neurological diseases market estimates and forecasts 2021 to 2033 (USD Million)
                    7.6. Immunological Diseases
                        7.6.1. Immunological diseases testing market estimates and forecasts 2021 to 2033 (USD Million)
                    7.7. Others
                        7.7.1. Others market estimates and forecasts 2021 to 2033 (USD Million)
Chapter 8. U.S. Biomarker-Based Immunoassays Market: End-use Estimates & Trend Analysis
                    8.1. Segment Dashboard
                    8.2. U.S. Biomarker-Based Immunoassays Market End-use Movement Analysis
                        8.2.1. U.S. Biomarker-Based Immunoassays Market Size & Trend Analysis, by End-use, 2021 to 2033 (USD Million)
                    8.3. Hospitals & Clinics
                        8.3.1. Hospitals and clinics market estimates and forecasts 2021 to 2033 (USD Million)
                    8.4. Diagnostic Laboratories
                        8.4.1. Diagnostic Laboratories market estimates and forecasts 2021 to 2033 (USD Million)
                    8.5. Research & Academic Institutes
                        8.5.1. Research & Academic Institutes market estimates and forecasts 2021 to 2033 (USD Million)
                    8.6. Others
                        8.6.1. Others market estimates and forecasts 2021 to 2033 (USD Million)
Chapter 9. Competitive Landscape
                    9.1. Company/Competition Categorization
                    9.2. Strategy Mapping
                    9.3. Company Market Share Analysis, 2024
                    9.4. List of Key Certification Providers/Scheme Owners
                    9.5. Company Profiles/Listing
                        9.5.1. F. Hoffmann-La Roche AG
                            9.5.1.1. Company overview
                            9.5.1.2. Financial performance
                            9.5.1.3. Product benchmarking
                            9.5.1.4. Strategic initiatives
                        9.5.2. Abbott
                            9.5.2.1. Company overview
                            9.5.2.2. Financial performance
                            9.5.2.3. Product benchmarking
                            9.5.2.4. Strategic initiatives
                        9.5.3. Thermo Fisher Scientific Inc
                            9.5.3.1. Company overview
                            9.5.3.2. Financial performance
                            9.5.3.3. Product benchmarking
                            9.5.3.4. Strategic initiatives
                        9.5.4. Eurofins Scientific
                            9.5.4.1. Company overview
                            9.5.4.2. Financial performance
                            9.5.4.3. Product benchmarking
                            9.5.4.4. Strategic initiatives
                        9.5.5. QIAGEN
                            9.5.5.1. Company overview
                            9.5.5.2. Financial performance
                            9.5.5.3. Product benchmarking
                            9.5.5.4. Strategic initiatives
                        9.5.6. Bio-Rad Laboratories, Inc.
                            9.5.6.1. Company overview
                            9.5.6.2. Financial performance
                            9.5.6.3. Product benchmarking
                            9.5.6.4. Strategic initiatives
                        9.5.7. Siemens Healthineers AG
                            9.5.7.1. Company overview
                            9.5.7.2. Financial performance
                            9.5.7.3. Product benchmarking
                            9.5.7.4. Strategic initiatives
                        9.5.8. Merck KGaA
                            9.5.8.1. Company overview
                            9.5.8.2. Financial performance
                            9.5.8.3. Product benchmarking
                            9.5.8.4. Strategic initiatives
                        9.5.9. PerkinElmer Inc.
                            9.5.9.1. Company overview
                            9.5.9.2. Financial performance
                            9.5.9.3. Product benchmarking
                            9.5.9.4. Strategic initiatives
                        9.5.10. Agilent Technologies, Inc.
                            9.5.10.1. Company overview
                            9.5.10.2. Financial performance
                            9.5.10.3. Product benchmarking
                            9.5.10.4. Strategic initiatives

List of Tables

Table 1 List of Secondary Sources
Table 2 List of Abbreviation
Table 3 U.S. biomarker-based immunoassays market, by sample, 2021 - 2033 (USD Million)
Table 4 U.S. biomarker-based immunoassays market, by product, 2021 - 2033 (USD Million)
Table 5 U.S. biomarker-based immunoassays market, by biomarkers, 2021 - 2033 (USD Million)
Table 6 U.S. biomarker-based immunoassays market, by diseases, 2021 - 2033 (USD Million)
Table 7 U.S. biomarker-based immunoassays market, by end use, 2021 - 2033 (USD Million)

List of Figures

Fig. 1 U.S. biomarker-based immunoassays market segmentation
Fig. 2 Data analysis biomarkers
Fig. 3 Market formulation and validation
Fig. 4 Data validating & publishing
Fig. 5 Market research process
Fig. 6 Information procurement
Fig. 7 Primary research
Fig. 8 Value-chain-based sizing & forecasting
Fig. 9 QFD biomarker modelling for market share assessment
Fig. 10 Market formulation & validation
Fig. 11 Commodity flow analysis
Fig. 12 Market outlook
Fig. 13 Segment snapshot-1
Fig. 14 Segment snapshot-2
Fig. 15 Competitive landscape snapshot
Fig. 16 Market trends & outlook
Fig. 17 Porter’s five force analysis
Fig. 18 PESTEL analysis
Fig. 19 U.S. biomarker-based immunoassays market: Sample outlook key takeaways
Fig. 20 U.S. biomarker-based immunoassays market: Sample movement analysis
Fig. 21 Blood market estimates and forecasts, 2021 - 2033 (USD Million)
Fig. 22 Tissue market estimates and forecasts, 2021 - 2033 (USD Million)
Fig. 23 Saliva market estimates and forecasts, 2021 - 2033 (USD Million)
Fig. 24 Urine market estimates and forecasts, 2021 - 2033 (USD Million)
Fig. 25 U.S. biomarker-based immunoassays market: Product outlook key takeaways
Fig. 26 U.S. biomarker-based immunoassays market: Product movement analysis
Fig. 27 Consumables market estimates and forecasts, 2021 - 2033 (USD Million)
Fig. 28 Instruments/Analyzers market estimates and forecasts, 2021 - 2033 (USD Million)
Fig. 29 Reagent & kits market estimates and forecasts, 2021 - 2033 (USD Million)
Fig. 30 Services market estimates and forecasts, 2021 - 2033 (USD Million)
Fig. 31 U.S. biomarker-based immunoassays market: Biomarker outlook key takeaways
Fig. 32 U.S. biomarker-based immunoassays market: Biomarker movement analysis
Fig. 33 Safety & toxicity biomarkers market estimates and forecasts, 2021 - 2033 (USD Million)
Fig. 34 Efficacy & pharmacodynamic biomarkers market estimates and forecasts, 2021 - 2033 (USD Million)
Fig. 35 Predictive & prognostic biomarkers market estimates and forecasts, 2021 - 2033 (USD Million)
Fig. 36 Surrogate/Exploratory biomarkers estimates and forecasts, 2021 - 2033 (USD Million)
Fig. 37 U.S. biomarker-based immunoassays market: Biomarker outlook key takeaways
Fig. 38 U.S. biomarker-based immunoassays market: Biomarker movement analysis
Fig. 39 Cancer market estimates and forecasts, 2021 - 2033 (USD Million)
Fig. 40 Cardiovascular diseases market estimates and forecasts, 2021 - 2033 (USD Million)
Fig. 41 Neurological diseases market estimates and forecasts, 2021 - 2033 (USD Million)
Fig. 42 Immunological diseases estimates and forecasts, 2021 - 2033 (USD Million)
Fig. 43 Others market estimates and forecasts, 2021 - 2033 (USD Million)
Fig. 44 U.S. biomarker-based immunoassays market: End-use outlook key takeaways
Fig. 45 U.S. biomarker-based immunoassays market: End-use movement analysis
Fig. 46 Hospitals and clinics market estimates and forecasts, 2021 - 2033 (USD Million)
Fig. 47 Diagnostic laboratories market estimates and forecasts, 2021 - 2033 (USD Million)
Fig. 48 Research & academic institutes market estimates and forecasts, 2021 - 2033 (USD Million)
Fig. 49 Others estimates and forecasts, 2021 - 2033 (USD Million)
Fig. 50 Biomarker-based immunoassays market: Regional outlook and key takeaways, 2024